Cargando…

Therapeutic Efficacy of Intravesical Platelet-Rich Plasma Injections for Interstitial Cystitis/Bladder Pain Syndrome—A Comparative Study of Different Injection Number, Additives and Concentrations

Purpose: Intravesical platelet-rich plasma (PRP) injections have been demonstrated effective in relieving symptoms among patients with interstitial cystitis/bladder pain syndrome (IC/BPS). This study compared the clinical efficacy among different injection number, adding solution, and concentrations...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Yuan-Hong, Jhang, Jia-Fong, Lin, Teng-Yi, Ho, Han-Chen, Hsu, Yung-Hsiang, Kuo, Hann-Chorng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980355/ https://www.ncbi.nlm.nih.gov/pubmed/35392571 http://dx.doi.org/10.3389/fphar.2022.853776

Ejemplares similares

Changes in the Ultrastructure of the Bladder Urothelium in Patients with Interstitial Cystitis after Intravesical Injections of Platelet-Rich Plasma
por: Lee, Yu-Khun, et al.
Publicado: (2022)

The clinical application of intravesical botulinum toxin A injection in patients with overactive bladder and interstitial cystitis
por: Jiang, Yuan-Hong, et al.
Publicado: (2022)

Improved Urothelial Cell Proliferation, Cytoskeleton and Barrier Function Protein Expression in the Patients With Interstitial Cystitis/Bladder Pain Syndrome After Intravesical Platelet-Rich Plasma Injection
por: Jhang, Jia-Fong, et al.
Publicado: (2022)

Repeated intravesical injections of platelet-rich plasma improve symptoms and alter urinary functional proteins in patients with refractory interstitial cystitis
por: Jiang, Yuan-Hong, et al.
Publicado: (2020)

Corrigendum: Improved Urothelial Cell Proliferation, Cytoskeleton and Barrier Function Protein Expression in the Patients With Interstitial Cystitis/Bladder Pain Syndrome After Intravesical Platelet-Rich Plasma Injection
por: Jhang, Jia-Fong, et al.
Publicado: (2022)

Comparison of the Clinical Efficacy and Adverse Events between Intravesical Injections of Platelet-Rich Plasma and Botulinum Toxin A for the Treatment of Interstitial Cystitis Refractory to Conventional Treatment
por: Jhang, Jia-Fong, et al.
Publicado: (2023)

Treatment Outcomes of Intravesical Botulinum Toxin A Injections on Patients with Interstitial Cystitis/Bladder Pain Syndrome
por: Yu, Wan-Ru, et al.
Publicado: (2022)

Bladder Ultrastructure and Urinary Cytokine Abnormality in Patients with Recurrent Urinary Tract Infection and the Changes after Intravesical Platelet-Rich Plasma Injections
por: Jhang, Jia-Fong, et al.
Publicado: (2022)

Adverse Events of Intravesical OnabotulinumtoxinA Injection between Patients with Overactive Bladder and Interstitial Cystitis—Different Mechanisms of Action of Botox on Bladder Dysfunction?
por: Kuo, Yuh-Chen, et al.
Publicado: (2016)

Therapeutic potential of intravesical injections of platelet-rich plasma in the treatment of lower urinary tract disorders due to regenerative deficiency
por: Ke, Qian-Sheng, et al.
Publicado: (2019)

Pathomechanism of Interstitial Cystitis/Bladder Pain Syndrome and Mapping the Heterogeneity of Disease
por: Jhang, Jia-Fong, et al.
Publicado: (2016)

Clinical application of intravesical botulinum toxin type A for overactive bladder and interstitial cystitis
por: Chen, Jing-Liang, et al.
Publicado: (2020)

Usefulness of Urinary Biomarkers for Assessing Bladder Condition and Histopathology in Patients with Interstitial Cystitis/Bladder Pain Syndrome
por: Jiang, Yuan-Hong, et al.
Publicado: (2022)

Predictive Factors for a Satisfactory Treatment Outcome with Intravesical Botulinum Toxin A Injection in Patients with Interstitial Cystitis/Bladder Pain Syndrome
por: Wang, Hsiu-Jen, et al.
Publicado: (2019)

Current Understanding of the Pathophysiology and Novel Treatments of Interstitial Cystitis/Bladder Pain Syndrome
por: Jhang, Jia-Fong, et al.
Publicado: (2022)

Dysregulation of bladder corticotropin-releasing hormone receptor in the pathogenesis of human interstitial cystitis/bladder pain syndrome
por: Jhang, Jia-Fong, et al.
Publicado: (2019)

Intravesical Injection of Abobotulinumtoxin-A in Patients with Bladder Pain Syndrome/Interstitial Cystitis
por: Rahnama’i, Mohammad-Sajjad, et al.
Publicado: (2023)

Low-Energy Shock Wave Plus Intravesical Instillation of Botulinum Toxin A for Interstitial Cystitis/Bladder Pain Syndrome: Pathophysiology and Preliminary Result of a Novel Minimally Invasive Treatment
por: Jiang, Yuan-Hong, et al.
Publicado: (2022)

Possible Association between Bladder Wall Morphological Changes on Computed Tomography and Bladder-Centered Interstitial Cystitis/Bladder Pain Syndrome
por: Jhang, Jia-Fong, et al.
Publicado: (2021)

Urine biomarkers in ESSIC type 2 interstitial cystitis/bladder pain syndrome and overactive bladder with developing a novel diagnostic algorithm
por: Jiang, Yuan-Hong, et al.
Publicado: (2021)

Difference in electron microscopic findings among interstitial cystitis/bladder pain syndrome with distinct clinical and cystoscopic characteristics
por: Lee, Yu Khun, et al.
Publicado: (2021)

Electron microscopic characteristics of interstitial cystitis/bladder pain syndrome and their association with clinical condition
por: Jhang, Jia-Fong, et al.
Publicado: (2018)

Can We Use Urinary Cytokine/Chemokine Analysis in Discriminating Ulcer-Type Interstitial Cystitis/Bladder Pain Syndrome?
por: Jiang, Yuan-Hong, et al.
Publicado: (2022)

Interstitial Cystitis Can Be Improved With Intravesical Instillation of Platelet-Rich Plasma
por: Hardy, Timothy J
Publicado: (2022)

Sensory Receptor, Inflammatory, and Apoptotic Protein Expression in the Bladder Urothelium of Patients with Different Subtypes of Interstitial Cystitis/Bladder Pain Syndrome
por: Jiang, Yuan-Hong, et al.
Publicado: (2023)

Urine Oxidative Stress Biomarkers as Novel Biomarkers in Interstitial Cystitis/Bladder Pain Syndrome
por: Jiang, Yuan-Hong, et al.
Publicado: (2022)

Use of Urinary Cytokine and Chemokine Levels for Identifying Bladder Conditions and Predicting Treatment Outcomes in Patients with Interstitial Cystitis/Bladder Pain Syndrome
por: Yu, Wan-Ru, et al.
Publicado: (2022)

Revisiting the Role of Potassium Sensitivity Testing and Cystoscopic Hydrodistention for the Diagnosis of Interstitial Cystitis
por: Jiang, Yuan-Hong, et al.
Publicado: (2016)

Novel Applications of Non-Invasive Intravesical Botulinum Toxin a Delivery in the Treatment of Functional Bladder Disorders
por: Jhang, Jia-Fong, et al.
Publicado: (2021)

Use of Urinary Biomarkers in Discriminating Interstitial Cystitis/Bladder Pain Syndrome from Male Lower Urinary Tract Dysfunctions
por: Yu, Wan-Ru, et al.
Publicado: (2023)

Intravesical Injection of Botulinum Toxin Type A in Men without Bladder Outlet Obstruction and Post-Deobstructive Prostate Surgery
por: Lee, Hsiang-Ying, et al.
Publicado: (2023)

O’Leary-Sant Symptom Index Predicts the Treatment Outcome for Onabotulinumtoxin A Injections for Refractory Interstitial Cystitis/Bladder Pain Syndrome
por: Kuo, Yuh-Chen, et al.
Publicado: (2015)

Long-Term Efficacy and Safety of Repeated Intravescial OnabotulinumtoxinA Injections Plus Hydrodistention in the Treatment of Interstitial Cystitis/Bladder Pain Syndrome
por: Lee, Cheng-Ling, et al.
Publicado: (2015)

Efficacy of Intravesical Botulinum Toxin A Injection in the Treatment of Refractory Overactive Bladder in Children
por: Fan, Yu-Hua, et al.
Publicado: (2023)

Novel Treatment of Chronic Bladder Pain Syndrome and Other Pelvic Pain Disorders by OnabotulinumtoxinA Injection
por: Jhang, Jia-Fong, et al.
Publicado: (2015)

Smaller bladder capacity and stronger bladder contractility in patients with ketamine cystitis are associated with elevated TRPV1 and TRPV4
por: Yang, Hsueh-Hui, et al.
Publicado: (2021)

Factors Associated with Therapeutic Efficacy of Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Syndrome
por: Hsiao, Sheng-Mou, et al.
Publicado: (2016)

Cystoscopic hydrodistention characteristics provide clinical and long-term prognostic features of interstitial cystitis after treatment
por: Yu, Wan-Ru, et al.
Publicado: (2021)

Interstitial cystitis intravesical therapy
por: Ha, Tanya, et al.
Publicado: (2017)

Editorial Comment: Intravesical injections of platelet-rich plasma is effective and safe in treatment of interstitial cystitis refractory to conventional treatment-A prospective clinical trial
por: Riccetto, Cássio L. Z.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_p2r4tmdc29rqf4eo1ib7phgths